Responses
Clinical and epidemiological research
Extended report
Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study
Compose a Response to This Article
Other responses
No responses have been published for this article.